红日药业:PTS不是PD-L1。PTS是一种治疗肺癌、肝癌的新型抗癌药物,是高仿药物还是原创药物暂不详。目前国内市场有同类药物多自美国生产,根据医疗界医生透露,药物控制肺癌有特效,就是价格太贵!红日药业PTS有一种剂型巳经获批印证待发,有一种制型也受理二次发补。如果公司公告PTS获批生产时,那将是这类抗肿瘤药物在中...
红日药业: 血必净注射液的海外注册工作在美国等国家已经启动。 PTS不是PD-L1。PTS是一种治疗肺癌、肝癌的新型抗癌药物,是高仿药物还是原创药物暂不详。目前国内市场有同类药物多自美国生产,根据医疗界医生透露,药物控制肺癌有特效,就是价格太贵!红日药业PTS有一种剂型巳经获批印证待发,有一种制型也受理二次发补。...
红日药业:您好,公司在研一类新药PTS项目仍在进行国家药品监督管理局药审中心的第二次发补的研究和讨论,该项目研发团队正在竭尽全力克服多种困难以最快的速度完成此次发补工作。艾姆地芬片(PD-L1)项目处于一期临床研究阶段。请您持续关注公司的后续公告。感谢您的关注! (来自深交所互动易)答复时间 2020-11-17 16...
When analyzing TROP2 and PD-L1 (n=61), 15 pts (24.6%) were TROP2-M-H/PD-L1+, 28 (45.9%) were TROP2-M-H/PD-L1-, 5 (8.2%) were TROP2-L/PD-L1+, and 13 (21.3%) were TROP2-L/PD-L1-. When analyzing TROP2 and sTILs (n=54), 6 pts (11.1%) were TROP2-M-H/sTILs...
5.进入肿瘤领域,为口服小分子PD-L1铺路 以小投入,小股权,撬动大收益。独家,独特机制等first-in-class抗肿瘤产品,钟院士牵头临床研究,2年内国内上10亿销售不成问题。按照上述三方面利润计算,红日至少每年可以增厚2个亿的利润。 生意红日说的算,股价资本说的算。
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated find... Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1...
$红日药业(SZ300026)$一类新药PTS在美国已获得两项专利,国内一项专利,由钟南山院士研究20余年,一旦上市单品年销售额达15亿以上,红日药业PTS生产场地已通过验收,药品注册即将获批,主力早已知道,各机构纷纷建仓,全力压制股价,再加上国外出口证已拿,配方颗粒即将爆炸式增长,公司其他题材如kb,PD_L1等,每一个的成功,均...
Objectives The prognosis for women with recurrent or persistent EC after progressing on first-line chemotherapy is poor. The humanized monoclonal anti-programmed cell death ligand 1 (PD-L1) inhibitor, Atezo has demonstrated monotherapy antitumor activity with an acceptable safety profile in recurrent EC...
It is noted that the responses were independent of PD-L1 status. The patients have been on treatment from 6 to more than 42 weeks. Out of 19 patients, 13 patients were still on treatment. AK104 in combination with mXELOX had a manageable safety profile. Of the 21 patients, we observed...
The efficacy and safety of len plus pembro combination therapy will be evaluated in an open-label, phase 2 trial of pts with advanced melanoma that progressed on PD-1/PD-L1 inhibitor therapy (NCT03776136). Methods: Key inclusion criteria: age ≥18 years, histologically/cytologically confirmed ...